ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0367

Differences in Self-Reported Medication Nonadherence and its Drivers in Young Adults versus Older Adults with Systemic Lupus Erythematosus

Hannah Concannon1, Kai Sun2, Jennifer Rogers3, Megan Clowse4, Rachel Randell2, Mithu Maheswaranathan5, Lisa Criscione-Schreiber5, Nathaniel Harris6, Amanda Eudy7 and Rebecca Sadun2, 1Duke University School of Medicine, Chapel Hill, NC, 2Duke University, Durham, NC, 3Duke, Durham, NC, 4Duke University, Chapel Hill, NC, 5Duke University School of Medicine, Durham, NC, 6Duke University Medical Center, Durham, NC, 7Duke University, Raleigh, NC

Meeting: ACR Convergence 2025

Keywords: Patient reported outcomes, psychosocial factors, Surveys, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0357–0386) Patient Outcomes, Preferences, & Attitudes Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Medication adherence poses a challenge for patients with SLE, especially younger patients, who often experience both more active disease and more intensive treatments than their older counterparts. Risk factors associated with nonadherence in patients with SLE have been described; however, modifiable adherence barriers specific to young adults under 30 years old remain poorly understood. Thus, this study compared medication nonadherence and drivers of nonadherence by age group.

Methods: Participants in this study were enrolled in an academic SLE Registry at a large academic medical center in the United States. From February 2020 to June 2024, we prospectively collected responses to the DOSE-Nonadherence-SLE questionnaire, a clinical tool validated to measure both the extent of and the reasons for medication nonadherence in SLE. The questionnaire organizes reasons for nonadherence into Capability, Opportunity, and Motivation categories. We defined nonadherence as binary: Patients were considered nonadherent if they reported missing or skipping at least one dose of lupus medication over the past seven days in the extent of nonadherence domain. We calculated proportions and odds ratios for extent of nonadherence by decade of life and for reasons for nonadherence across age groups < 30 and ≥30 years old. We also used logistic regression to determine relationships of nonadherence with age and other covariates.

Results: Of the 336 completed unique DOSE-Nonadherence-SLE questionnaires, 55 (16%) were from patients < 30 years old (Table 1). Medication nonadherence differed significantly across age groups 18-30, 30-40, 40-50, and 50+ (p< 0.01); for each increased year of age, self-reported nonadherence decreased by 2% (p< 0.05). Black race and Hispanic ethnicity were also predictive of nonadherence (Table 2). Across age groups, the most common reasons for nonadherence were “I forgot or I was busy” (69%), “I do not have a regular schedule (28%), and “I am tired of taking medicines every day” (27%). Patients < 30 were more likely to report nonadherence due to inability to fill a medication on time (41% vs. 16%, OR 3.72; 95% CI: 1.53, 9.02) and due to needing to take a medicine with food but not being able to eat (38% vs. 19%, OR 2.55; 95% CI: 1.06, 6.13) (Figure 1).

Conclusion: Younger patients reported greater extent of medication nonadherence, often due to logistical impediments. In addition to counseling on the importance of medication adherence, rheumatologists should, when possible, provide support to help young adults with SLE overcome challenges in obtaining and taking medicines. Approaches to understanding and intervening on medication nonadherence in SLE may need to be tailored by age.

Supporting image 1Figure 1. Reasons for nonadherence per DOSE-nonadherence-SLE self-reports for patients < 30 vs. patients 30 years old and over.

Reasons for nonadherence are organized by reason category (Capability, Opportunity, or Motivation) and listed in descending order by odds ratios within each category. *denotes p < 0.05, **denotes p < 0.005

Supporting image 2Table 1. Cohort demographics and characteristics.

Values presented as n (%) unless otherwise indicated.

Supporting image 3Table 2. Results of logistic regression for extent of nonadherence.

Significant odds ratios are bolded. *Multivariable analysis includes only those variables with p-value < 0.05 in the univariate models.


Disclosures: H. Concannon: None; K. Sun: Aurinia, 2; J. Rogers: AstraZeneca, 1, 1, Aurinia, 2, 5, Exagen, 5, Immunovant, 2, 5; M. Clowse: None; R. Randell: biogen, 12, My husband is employed at Biogen and owns a small amount of stock < $10,000; M. Maheswaranathan: AstraZeneca, 2, UCB, 2; L. Criscione-Schreiber: UCB, 5; N. Harris: None; A. Eudy: Aurinia, 2, GlaxoSmithKlein(GSK), 5, Immunovant, 5; R. Sadun: The Expert Institute, 12,.

To cite this abstract in AMA style:

Concannon H, Sun K, Rogers J, Clowse M, Randell R, Maheswaranathan M, Criscione-Schreiber L, Harris N, Eudy A, Sadun R. Differences in Self-Reported Medication Nonadherence and its Drivers in Young Adults versus Older Adults with Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/differences-in-self-reported-medication-nonadherence-and-its-drivers-in-young-adults-versus-older-adults-with-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/differences-in-self-reported-medication-nonadherence-and-its-drivers-in-young-adults-versus-older-adults-with-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology